[go: up one dir, main page]

WO1998029110A3 - Preparation et methode de traitement de neoplasmes par inhalation - Google Patents

Preparation et methode de traitement de neoplasmes par inhalation Download PDF

Info

Publication number
WO1998029110A3
WO1998029110A3 PCT/US1997/024289 US9724289W WO9829110A3 WO 1998029110 A3 WO1998029110 A3 WO 1998029110A3 US 9724289 W US9724289 W US 9724289W WO 9829110 A3 WO9829110 A3 WO 9829110A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhalation
formulation
treating neoplasms
composition
neoplasms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/024289
Other languages
English (en)
Other versions
WO1998029110A2 (fr
Inventor
Michael E Placke
Anthony R Imondi
Michael J Brooker
John E Frye
Praful K Shah
Douglas R Flanagan Jr
Maureen D Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Battelle Memorial Institute Inc
Original Assignee
Battelle Memorial Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Memorial Institute Inc filed Critical Battelle Memorial Institute Inc
Priority to JP53035898A priority Critical patent/JP2001513078A/ja
Priority to DE69737510T priority patent/DE69737510T2/de
Priority to BR9713661-1A priority patent/BR9713661A/pt
Priority to NZ336381A priority patent/NZ336381A/xx
Priority to CA002275889A priority patent/CA2275889C/fr
Priority to EP97955033A priority patent/EP0954283B1/fr
Priority to AU70975/98A priority patent/AU741439B2/en
Publication of WO1998029110A2 publication Critical patent/WO1998029110A2/fr
Publication of WO1998029110A3 publication Critical patent/WO1998029110A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une préparation, une méthode et un appareil de traitement de néoplasmes tels que le cancer par absorption, par l'administration par inhalation, d'une quantité efficace du point de vue pharmaceutique d'une composition très toxique, la composition se constituant d'un médicament antinéoplasique non encapsulé.
PCT/US1997/024289 1996-12-30 1997-12-30 Preparation et methode de traitement de neoplasmes par inhalation Ceased WO1998029110A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP53035898A JP2001513078A (ja) 1996-12-30 1997-12-30 吸入により新生物を治療する製剤とその方法
DE69737510T DE69737510T2 (de) 1996-12-30 1997-12-30 Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
BR9713661-1A BR9713661A (pt) 1996-12-30 1997-12-30 Formulação e método para o tratamento de neoplasmas por inalação
NZ336381A NZ336381A (en) 1996-12-30 1997-12-30 Formulation and method for treating neoplasms by inhalation
CA002275889A CA2275889C (fr) 1996-12-30 1997-12-30 Preparation et methode de traitement de neoplasmes par inhalation
EP97955033A EP0954283B1 (fr) 1996-12-30 1997-12-30 Utilisation d'un agent anti-cancereux non encapsule pour la preparation d'une composition pour le traitement de neoplasmes par inhalation
AU70975/98A AU741439B2 (en) 1996-12-30 1997-12-30 Formulation and method for treating neoplasms by inhalation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3378996P 1996-12-30 1996-12-30
US60/033,789 1996-12-30

Publications (2)

Publication Number Publication Date
WO1998029110A2 WO1998029110A2 (fr) 1998-07-09
WO1998029110A3 true WO1998029110A3 (fr) 1999-04-15

Family

ID=21872447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/024289 Ceased WO1998029110A2 (fr) 1996-12-30 1997-12-30 Preparation et methode de traitement de neoplasmes par inhalation

Country Status (12)

Country Link
US (5) US6471943B1 (fr)
EP (1) EP0954283B1 (fr)
JP (1) JP2001513078A (fr)
CN (1) CN1245423A (fr)
AT (1) ATE357214T1 (fr)
AU (1) AU741439B2 (fr)
BR (1) BR9713661A (fr)
CA (2) CA2628857C (fr)
DE (1) DE69737510T2 (fr)
ES (1) ES2285743T3 (fr)
NZ (1) NZ336381A (fr)
WO (1) WO1998029110A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7537009B2 (en) 2001-06-05 2009-05-26 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7581540B2 (en) 2004-08-12 2009-09-01 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
WO2000019991A1 (fr) * 1998-10-02 2000-04-13 Battelle Memorial Institute Chimiotherapie par inhalation pour la prevention et le traitement des tumeurs metastatiques du poumon
AU2986800A (en) * 1999-02-08 2000-08-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of inhibiting the hgf-met-upa-plasmin network
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
JP2003523330A (ja) 2000-02-04 2003-08-05 チルドレンズ・ホスピタル・リサーチ・ファウンデイション アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
DE60142043D1 (de) * 2000-04-03 2010-06-17 Battelle Memorial Inst Columbu Ausgabevorrichtungen und flüssigformulierungen
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
JP2004526674A (ja) * 2000-12-01 2004-09-02 バテル・メモリアル・インスティテュート 液体処方物中における生体分子の安定化のための方法
US20040234497A1 (en) * 2001-05-04 2004-11-25 Yi Luo Hyaluronic acid containing bioconjugates:targeted delivery of anti-cancer drugs to cancer cells
AU2002323266B2 (en) * 2001-08-20 2008-04-24 Transave, Inc. Method for treating lung cancers
EP1424898A4 (fr) * 2001-08-20 2008-04-02 Transave Inc Traitement du cancer par inhalation de formulations stables contenant platine
JP2005508354A (ja) * 2001-10-15 2005-03-31 クリチテック インコーポレーテッド 水に溶けにくい薬物の送込み用組成物および方法並びに治療方法
CN100506284C (zh) 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
CA2474508A1 (fr) * 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycines a proprietes pharmacologiques et biologiques ameliorees
EP1487413A4 (fr) * 2002-03-05 2010-11-10 Transave Inc Systeme d'inhalation pour le traitement d'infections intracellulaires
ITPI20020018A1 (it) * 2002-03-28 2002-06-26 Azienda Ospedaliera Pisana Ventilazione polmonare a variazione di flusso
GB0208516D0 (en) * 2002-04-15 2002-05-22 Univ Liverpool Chemotherapy
CA2483696A1 (fr) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocage au moyen de gags non ha et augmentation de l'efficacite d'agents anticancereux conjugues ha
US6985798B2 (en) 2002-05-10 2006-01-10 Oriel Therapeutics, Inc. Dry powder dose filling systems and related methods
US7677411B2 (en) * 2002-05-10 2010-03-16 Oriel Therapeutics, Inc. Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders
US7118010B2 (en) 2002-05-10 2006-10-10 Oriel Therapeutics, Inc. Apparatus, systems and related methods for dispensing and /or evaluating dry powders
US6889690B2 (en) * 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
SI1534366T1 (sl) * 2002-06-27 2014-04-30 Oriel Therapeutics, Inc. Sistem za polnjenje doze s suhim praškom in ustrezni postopek
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
AU2003302314A1 (en) * 2002-08-02 2004-07-09 Transave, Inc. Platinum aggregates and process for producing the same
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
DK1581236T3 (da) * 2002-10-29 2013-12-02 Insmed Inc Opretholdt afgivelse af antiinfektionsmidler
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US20060179491A1 (en) * 2002-11-12 2006-08-10 Brian Graham Process for treating non-human animals
US7353533B2 (en) 2002-12-18 2008-04-01 Novell, Inc. Administration of protection of data accessible by a mobile device
US7185650B2 (en) * 2002-12-19 2007-03-06 Arie Huber Systems and methods for determining a minimum effective dose of an inhaled drug for an individual patient at a given time
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20040187864A1 (en) * 2003-03-24 2004-09-30 Cindet, Llc Inhalation device and method
SI2263694T1 (sl) * 2003-09-25 2013-09-30 Astellas Pharma Inc. Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin
US7377277B2 (en) * 2003-10-27 2008-05-27 Oriel Therapeutics, Inc. Blister packages with frames and associated methods of fabricating dry powder drug containment systems
US7451761B2 (en) * 2003-10-27 2008-11-18 Oriel Therapeutics, Inc. Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances
US20050249822A1 (en) * 2004-03-18 2005-11-10 Transave, Inc. Administration of cisplatin by inhalation
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20060045849A1 (en) * 2004-08-24 2006-03-02 Farhan Taghizadeh Method of customizing the fragrance of nasal medications
CA2584673A1 (fr) * 2004-11-08 2006-05-26 Transave, Inc. Methodes de traitement du cancer avec des formulations de composes de platine a base lipipique administrees par voie intraperitoneale
CN101189006A (zh) * 2005-04-07 2008-05-28 康福玛医药公司 基于磷脂的药物制剂及其生产和使用方法
US20060283742A1 (en) * 2005-06-16 2006-12-21 Canel Lightning Co. Ltd. Multi-lamp display packaging for lamps with collapsible lampshades
US20090180964A1 (en) * 2005-06-24 2009-07-16 Rao Papineni Transmucosal delivery of optical, spect, multimodal,drug or biological cargo laden nanoparticle(s) in small animals or humans
WO2007056236A2 (fr) * 2005-11-08 2007-05-18 Transave, Inc. Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides administree par voie intraveineuse
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056263A2 (fr) * 2005-11-08 2007-05-18 Transave, Inc. Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides d'une haute activite administrees par voie intraveineuse
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007064658A2 (fr) * 2005-11-30 2007-06-07 Transave, Inc. Procedes efficaces et sans risques d'administation d'agents therapeutiques
EP1954265A2 (fr) * 2005-12-01 2008-08-13 Conforma Therapeutics Corporation Compositions contenant de l'ansamycine
ES2594368T3 (es) 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
US10821132B2 (en) 2007-02-26 2020-11-03 Heartbeet Ltd Compositions of nitrates and methods of use thereof
WO2008105730A1 (fr) 2007-02-26 2008-09-04 Jon Lundberg Composition améliorant la performance et utilisation de celle-ci
US11759477B2 (en) 2007-02-26 2023-09-19 Heartbeet Ltd. Compositions of nitrates and methods of use thereof
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
EP2121088B1 (fr) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Unité chauffante à utiliser dans un dispositif d'administration de médicament
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions
WO2008134630A1 (fr) * 2007-04-30 2008-11-06 Apt Pharmaceuticals Composés de dexrazoxane pour une cardioprotection
WO2008137717A1 (fr) * 2007-05-04 2008-11-13 Transave, Inc. Compositions de médicaments multicationiques pour réduire des interactions avec des biomolécules polyanioniques et leurs procédés et utilisations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
EP2230934B8 (fr) 2007-12-14 2012-10-24 AeroDesigns, Inc Administration de produits alimentaires sous forme d'aérosols
CN105879044A (zh) * 2008-10-07 2016-08-24 瑞沙恩医药公司 Hpma-多西他赛或吉西他滨缀合物及其用途
BR112012008772A2 (pt) 2009-10-13 2017-06-20 Rexahn Pharmaceuticals Inc sistemas poliméricos para a liberação de agentes anti-câncer
WO2013177226A1 (fr) 2012-05-21 2013-11-28 Insmed Incorporated Systèmes de traitement d'infections pulmonaires
EP2892524B1 (fr) 2012-09-04 2020-11-25 Eleison Pharmaceuticals, LLC Prévention de la rechute du cancer pulmonaire avec un complexe lipide/cisplatine
CN104837483B (zh) 2012-11-20 2017-09-01 光谱医药公司 制备治疗用途的脂质体封装式长春新碱的改进方法
AU2013352259B2 (en) 2012-11-29 2018-06-14 Insmed Incorporated Stabilized vancomycin formulations
AU2013359048A1 (en) * 2012-12-13 2015-07-02 Cytrx Corporation Anthracycline formulations
CN113842392A (zh) 2013-06-05 2021-12-28 西特克斯公司 用于治疗癌症的细胞毒素剂
US20160022720A1 (en) * 2013-08-02 2016-01-28 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
CN106061482A (zh) 2013-10-08 2016-10-26 拉姆医疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
US20150265582A1 (en) 2014-02-11 2015-09-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
ES2952025T3 (es) 2014-04-04 2023-10-26 Ai Therapeutics Inc Una formulación de rapamicina inhalable para tratar condiciones relacionadas con la edad
TWI601542B (zh) * 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
KR102657132B1 (ko) 2014-05-15 2024-04-12 인스메드 인코포레이티드 폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법
BR112017006842A2 (pt) 2014-10-07 2017-12-12 Lam Therapeutics Inc formulação de rapamicina inalável para o tratamento de hipertensão pulmonar
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (fr) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycine destinée au traitement de la lymphangioléiomyomatose
US10751319B2 (en) 2015-06-04 2020-08-25 Crititech, Inc. Collection device and methods for use
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
JP7001593B2 (ja) 2015-08-11 2022-01-19 コグノア， インコーポレイテッド 人工知能およびユーザ入力を用いて発達進度を判定するための方法および装置
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
WO2017176628A1 (fr) 2016-04-04 2017-10-12 Crititech, Inc. Méthodes de traitement de tumeurs solides
EP3539033B1 (fr) 2016-11-14 2024-10-02 Cognoa, Inc. Procédés et appareil pour l'évaluation de conditions de développement et fournissant un contrôle sur la couverture et la fiabilité
US10874768B2 (en) * 2017-01-20 2020-12-29 Covidien Lp Drug eluting medical device
US20220254461A1 (en) * 2017-02-09 2022-08-11 Cognoa, Inc. Machine learning algorithms for data analysis and classification
CA3053245A1 (fr) * 2017-02-09 2018-08-16 Cognoa, Inc. Plate-forme et systeme de medecine personnalisee numerique
CN110730679A (zh) 2017-06-09 2020-01-24 克里蒂泰克公司 囊内注射抗肿瘤颗粒治疗上皮囊肿
CN110799176A (zh) 2017-06-14 2020-02-14 克里蒂泰克公司 治疗肺部疾病的方法
US10894019B2 (en) 2017-08-15 2021-01-19 University Of South Carolina Drug delivery system and method for targeting cancer stem cells
RU2020110399A (ru) 2017-10-03 2021-11-09 Крититек, Инк. Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
KR102852740B1 (ko) 2018-02-02 2025-08-29 알렉스자 파마스티칼즈, 인크. 전기적 응축 에어로졸 디바이스
JP7460534B2 (ja) 2018-03-30 2024-04-02 インスメッド インコーポレイテッド リポソーム医薬品の連続製造方法
WO2020198065A1 (fr) 2019-03-22 2020-10-01 Cognoa, Inc. Procédés et dispositifs de thérapie numérique personnalisée
US11672767B2 (en) 2019-05-13 2023-06-13 University Of South Carolina Enzymatically cleavable self-assembled nanoparticles for morphogen delivery
WO2021040673A1 (fr) * 2019-08-26 2021-03-04 Alain Martin Méthodes de traitement de l'hypoxémie chronique et d'inhibition de la fibrose pulmonaire chez des patients atteints de fibrose pulmonaire avec et sans bpco
CN111067879B (zh) * 2020-01-20 2022-08-09 珠海瑞思普利医药科技有限公司 一种抗肿瘤组合物吸入粉雾剂及其制备方法
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US4975421A (en) * 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing
WO1993017665A1 (fr) * 1992-03-06 1993-09-16 Sievers Robert E Procedes et appareils d'administration de medicaments utilisant des solutions supercritiques
WO1993021938A1 (fr) * 1992-05-04 1993-11-11 Adria Laboratories Procedes de traitement du cancer au moyen de l'epirubicine a haute dose
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5283383A (en) * 1992-02-13 1994-02-01 The United States Of America As Represented By The Department Of Health And Human Services Antitumor compound, compositions and method of use
WO1994010175A1 (fr) * 1992-10-23 1994-05-11 The United States Of America, As Represented By The Secretary Of Health And Human Services Inhibiteurs de la topo-isomerase ii et leurs utilisations therapeutiques
US5348946A (en) * 1991-02-28 1994-09-20 Biochem Immunosystems, Inc. Heteroanthracycline antitumor analogs
EP0645145A2 (fr) * 1993-09-29 1995-03-29 Bristol-Myers Squibb Company Composition pharmaceutique stabilisée et solvant stabilisant
US5438072A (en) * 1992-12-02 1995-08-01 Rhone-Poulenc Rorer S.A. Taxoid-based compositions
EP0709090A2 (fr) * 1994-10-14 1996-05-01 Eli Lilly And Company Compositions pour le traitement de tumeurs résistantes
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4246399A (en) 1977-03-21 1981-01-20 Interx Research Corporation Complexes of doxorubicin exhibiting enhanced stability
JPS5795920A (en) 1980-12-04 1982-06-15 Teijin Ltd Remedy for respiratory disease
US4649911A (en) 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
DE3686025T2 (de) * 1985-05-22 1993-01-07 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US5124317A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124318A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.R.L. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
GB8519452D0 (en) 1985-08-02 1985-09-11 Erba Farmitalia Injectable solutions
US4739046A (en) 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4826817A (en) 1986-02-07 1989-05-02 Brown Thomas E Amino acid and hydroxyamino acid transporter compounds for therapeutic applications, process and use
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5115971A (en) 1988-09-23 1992-05-26 Battelle Memorial Institute Nebulizer device
US5511726A (en) 1988-09-23 1996-04-30 Battelle Memorial Institute Nebulizer device
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5171737A (en) 1989-03-03 1992-12-15 The Liposome Company, Inc. Emulsions
CA2058764A1 (fr) 1989-04-28 1990-10-29 Peter D. Hodson Dispositif servant a inhaler des poudres
ATE190496T1 (de) 1989-12-20 2000-04-15 Autoimmune Inc Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
US5593970A (en) 1990-06-11 1997-01-14 Biochem Pharma Inc. Heterocyclic anthracycline analogs
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
EP0525960B1 (fr) 1991-06-18 1996-03-20 American Home Products Corporation Utilisation de rapamycine pour le traitement de la lymphome/leucéme des cellules T adultes
US5681812A (en) 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5606037A (en) 1992-11-09 1997-02-25 Biochem Pharma Inc. Processes antineoplastic heteronaphthoquinones
ES2119996T3 (es) 1992-11-27 1998-10-16 Napro Biotherapeutics Inc Composicion inyectable que comprende faclitaxel.
ES2129117T3 (es) 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
US5591737A (en) 1992-12-17 1997-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5594139A (en) 1993-01-29 1997-01-14 Agouron Pharmaceuticals, Inc. Processes for preparing antiproliferative garft-inhibiting compounds
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5531219A (en) * 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
JPH08301762A (ja) * 1995-05-12 1996-11-19 Teijin Ltd 肺癌治療剤
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US4975421A (en) * 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5348946A (en) * 1991-02-28 1994-09-20 Biochem Immunosystems, Inc. Heteroanthracycline antitumor analogs
US5283383A (en) * 1992-02-13 1994-02-01 The United States Of America As Represented By The Department Of Health And Human Services Antitumor compound, compositions and method of use
WO1993017665A1 (fr) * 1992-03-06 1993-09-16 Sievers Robert E Procedes et appareils d'administration de medicaments utilisant des solutions supercritiques
WO1993021938A1 (fr) * 1992-05-04 1993-11-11 Adria Laboratories Procedes de traitement du cancer au moyen de l'epirubicine a haute dose
WO1994010175A1 (fr) * 1992-10-23 1994-05-11 The United States Of America, As Represented By The Secretary Of Health And Human Services Inhibiteurs de la topo-isomerase ii et leurs utilisations therapeutiques
US5438072A (en) * 1992-12-02 1995-08-01 Rhone-Poulenc Rorer S.A. Taxoid-based compositions
EP0645145A2 (fr) * 1993-09-29 1995-03-29 Bristol-Myers Squibb Company Composition pharmaceutique stabilisée et solvant stabilisant
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
EP0709090A2 (fr) * 1994-10-14 1996-05-01 Eli Lilly And Company Compositions pour le traitement de tumeurs résistantes

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
A.KINOSHITA: "Investigation of cisplatin inhalation chemotherapy effects on mice after air passage implantation of FM3A mice", J.JPN.SOC. CANCER THER., vol. 28, no. 4, 1993, pages 705 - 715, XP002078723 *
C.LI ET AL.: "Synthesis and evaluation of PEG-paclitaxel conjugate as a water soluble pactitaxel prodrug", PROC ANNU MEET AM ASSOC CANCER RES, vol. 37, 1996, pages 376, XP002094516 *
CRAIG LEWIS: "A review of the use of chemoprotectants in cancer chemotherapy", DRUG SAFETY, vol. 11, no. 3, 1994, pages 153 - 162, XP002094514 *
Database Cancerlit accession no. 71800442 & Ochanomizu Med. J., 18(3), p.103-114, 1970 *
G.T.BUDD ET AL.: "Clinical effects of amifostine (Ethyol) in patients treated with carboplatin", EUR J CANCER, vol. 32A, no. suppl. 4, 1996, pages S43 - S45, XP002094515 *
Medline Database Accession no. 83269156 *
S.OKUYUMA ET AL.: "Reinforcing aerosol cisplatin for radiotherapy of laryngeal cancer", TOHOKU J EXP MED, vol. 169, no. 3, 1993, pages 253 - 255, XP002094449 *
SHEVCHENKO ET AL.: "Inhalation of chemical substances and oxygen in radiotherapy of bronchial cancer", NEOPLASMA, vol. 15, no. 4, 1968, pages 419 - 426, XP002078721 *
T.TATSAMURA ET AL.: "Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical", BR.J.CANCER, vol. 68, no. 6, 1993, pages 1146 - 1149, XP002094448 *
T.TATSAMURA ET AL.: "New chemotherapeutic method for the treatment of tracheal and bronchial cancers--nebulization chemotherapy", GAN NO RINSHO, vol. 29, no. 7, 1983, pages 765 - 770 *
TATSUMURA ET AL.: "Further evaluation of the efficacy of nebulization chemotherapy in the treatment of lung cancer", CHEST, vol. 106, no. 2 suppl., 1994, pages 70s, XP002078722 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US9440034B2 (en) 2001-05-24 2016-09-13 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US9308208B2 (en) 2001-06-05 2016-04-12 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US8955512B2 (en) 2001-06-05 2015-02-17 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US7537009B2 (en) 2001-06-05 2009-05-26 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US9439907B2 (en) 2001-06-05 2016-09-13 Alexza Pharmaceutical, Inc. Method of forming an aerosol for inhalation delivery
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9370629B2 (en) 2003-05-21 2016-06-21 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7581540B2 (en) 2004-08-12 2009-09-01 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages

Also Published As

Publication number Publication date
EP0954283A2 (fr) 1999-11-10
US6471943B1 (en) 2002-10-29
CA2628857C (fr) 2011-09-13
EP0954283B1 (fr) 2007-03-21
CA2275889A1 (fr) 1998-07-09
US6348209B2 (en) 2002-02-19
US6419901B2 (en) 2002-07-16
CA2628857A1 (fr) 1998-07-09
ATE357214T1 (de) 2007-04-15
NZ336381A (en) 2000-11-24
WO1998029110A2 (fr) 1998-07-09
JP2001513078A (ja) 2001-08-28
AU7097598A (en) 1998-07-31
CN1245423A (zh) 2000-02-23
US20020155066A1 (en) 2002-10-24
AU741439B2 (en) 2001-11-29
US6419900B2 (en) 2002-07-16
US20010036444A1 (en) 2001-11-01
US20010038826A1 (en) 2001-11-08
DE69737510D1 (de) 2007-05-03
DE69737510T2 (de) 2007-12-06
CA2275889C (fr) 2008-03-18
BR9713661A (pt) 2000-10-24
ES2285743T3 (es) 2007-11-16
US20010038827A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
WO1998029110A3 (fr) Preparation et methode de traitement de neoplasmes par inhalation
WO2001066103A3 (fr) Formulation et methode de traitement des neoplasmes par inhalation
CA2186260A1 (fr) Composition contenant de la morphine, du polypyrrolidone et un polyalyleneoxyde
CA2301057A1 (fr) Procede permettant d'administrer un taxane liposomal encapsule
WO2002056912A3 (fr) Methode de traitement du cancer
AU1534699A (en) Osmotic dosage form comprising first and second coats
HUP9601884A2 (en) 6-(dimethylamino-methyl)-1-phenyl-cyclohexane compounds, their use as pharmaceutically active analgetic matarials and process for their preparation
CA2277824A1 (fr) Formulation destinee a un apport nasal et procede d'utilisation associe
AU3136897A (en) Compositions, methods and devices for the transdermal delivery of drugs
NZ504076A (en) A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition
HUP9903377A3 (en) The mesylate salt of a macrocyclic bis-indolyl-maleimide derivative, process for its preparation, use thereof and pharmaceutical compositions containing the compound
CA2154424A1 (fr) 1-phenyl-3-dimethylaminopropane possedant des proprietes pharmaceutiques
CA2180535A1 (fr) Procede de traitement du psoriasis par omeprazole ou autres composes apparentes
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
CA2117891A1 (fr) Methode de traitement du cancer par therapie combinee au moyen de derives de 2'-halomethylidene et d'un agent antineoplasique specifique de la phase s ou de la phase m
WO1999022722A3 (fr) Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire
WO1999063976A3 (fr) Traitement de diabetes
CA2157142A1 (fr) Traitement des maladies causees par les desordres de la glande sebacee
WO1999033450A3 (fr) Agents therapeutiques
AU2162700A (en) Supramolecular complexes containing therapeutic agents
HUP9602868A3 (en) 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation
NZ314488A (en) Anticancer medicaments containing alpha1-adrenoreceptor antagonist compounds
AU8851298A (en) L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
ZA969319B (en) Derivatives of imidazole n-benzyldioxole, their preparation process, their use as medicaments, pharmaceutical composition and new use.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97181614.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 70975/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 336381

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2275889

Country of ref document: CA

Ref document number: 2275889

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/006122

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1998 530358

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997955033

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997955033

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 70975/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1997955033

Country of ref document: EP